Danone reports 1H revenue EUR 13.737M vs EUR 13.757M last year

Reports 1H recurring EPS EUR 1.91 vs EUR 1.80 last year. H1 2025 sales of EUR 13,737m up +4.2% on a like-for-like basis, with volume/mix up +2.6%, and price up +1.7%; Q2 sales up +4.1% LFL, with strong volume/mix of +3.2%, and positive price of +1.0%. CEO Antoine de Saint-Affrique said, “We started chapter two of the Renew Danone (DANOY) strategy with a strong performance, demonstrating consistency in driving quality growth and reflecting the strength and resilience of our health-focused portfolio: sales for the first half increased by +4.2% on a like-for-like basis, driven by volume-mix up +2.6%. In a volatile and uncertain environment, we are consistently doubling down on our fundamentals, further fueling our winning platforms such as high protein, medical nutrition, Alpro and Aptamil, while moving forward with this next chapter of our strategy. We started actively complementing our portfolio, further investing in medical nutrition, acquiring Kate Farms in the US, and in next-generation biotics through The Akkermansia Company. We remain focused on the consistent execution of our consumer-centric and science-based strategy and the delivery of our mid-term guidance.